{"id":7796,"date":"2026-02-24T06:08:27","date_gmt":"2026-02-24T06:08:27","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/cjc-1295-with-dac\/"},"modified":"2026-04-09T14:26:02","modified_gmt":"2026-04-09T21:26:02","slug":"cjc-1295-with-dac","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 with DAC \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to CJC-1295 with DAC product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on CJC-1295 with DAC \u2014 for educational purposes only<\/p>\n

\nDrug Affinity Complex (DAC) Albumin-Binding Technology<\/summary>\n
\n

The DAC technology utilizes a reactive maleimide linker attached to the peptide that covalently binds to Cys34 of circulating serum albumin. This prevents glomerular filtration (albumin MW ~66 kDa exceeds renal threshold) and protects the peptide from proteolysis. The conjugation reaction is essentially irreversible under physiological conditions. Pharmacokinetic studies in animal models show that >90% of CJC-1295-DAC becomes albumin-bound within minutes. Research compound \u2014 not for human use.<\/p>\n

Jette L et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.” Endocrinology.<\/em> 2005. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nGHRH Receptor Pharmacology and GH\/IGF-1 Axis<\/summary>\n
\n

CJC-1295 is a modified GHRH(1-29) analog that activates the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor on anterior pituitary somatotrophs. Receptor activation stimulates G\u03b1s-mediated cAMP production and subsequent GH gene transcription and secretory granule exocytosis. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) confer resistance to DPP-IV cleavage and improve receptor binding affinity compared to native GHRH(1-29). Research compound \u2014 not for human use.<\/p>\n

Teichman SL et al. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone.” J Clin Endocrinol Metab.<\/em> 2006. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nCJC-1295 in GHRH Knockout Mouse Models<\/summary>\n
\n

Studies using GHRH knockout (GHRH-KO) mice\u2014which have severe GH deficiency, dwarfism, and virtually undetectable IGF-1\u2014demonstrated that CJC-1295 administration partially restored somatic growth. Treatment increased body weight, femur length, and pituitary GH mRNA expression. The results confirmed that the somatotroph population in GHRH-KO mice retained functional GHRH receptors capable of responding to exogenous GHRH analogs despite the absence of endogenous hypothalamic GHRH. Research compound \u2014 not for human use.<\/p>\n

Alba M et al. “Administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab.<\/em> 2006. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to CJC-1295 with DAC product page Research Library Published research on CJC-1295 with DAC \u2014 for educational purposes only Drug Affinity Complex (DAC) Albumin-Binding Technology The DAC technology utilizes a reactive maleimide linker attached to the peptide that covalently binds to Cys34 of circulating serum albumin. This prevents glomerular filtration (albumin MW ~66 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7796","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7796"}],"version-history":[{"count":2,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7796\/revisions"}],"predecessor-version":[{"id":8627,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7796\/revisions\/8627"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}